Patient considerations in metastatic colorectal cancer – role of panitumumab

Patient considerations in metastatic colorectal cancer – role of panitumumab

Jane E Rogers Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Epidermal growth factor receptor (EGFR) is overexpressed in many malignancies, including colorectal cancer (CRC), making EGFR an attractive treatment option. Panitumumab and cetuxima...

Full description

Bibliographic Details
Main Author:	Rogers JE
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-04-01
Series:	OncoTargets and Therapy
Subjects:	panitumumab antineoplastic agent antibodies monoclonal colorectal neoplasms
Online Access:	https://www.dovepress.com/patient-considerations-in-metastatic-colorectal-cancer-ndash-role-of-p-peer-reviewed-article-OTT

Similar Items

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study
by: M. Yu. Fedyanin, et al.
Published: (2019-06-01)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
by: Battaglin F, et al.
Published: (2019-06-01)

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
by: Françoso A, et al.
Published: (2017-01-01)

<it>EGFR</it> gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
by: Yang Zu-Yao, et al.
Published: (2012-08-01)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler Josef, et al.
Published: (2012-09-01)

STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
by: V. A. Gorbunova
Published: (2015-05-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
by: Munenobu Kashiwa, et al.
Published: (2021-10-01)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
by: Francesca Battaglin, et al.
Published: (2018-01-01)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
by: Ho Wai Derrick Siu, et al.
Published: (2021-08-01)

Combination chemotherapy for metastatic colorectal cancer
by: Koehne Claus-Henning
Published: (2003-01-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

Second-line panitumumab as a triweekly dose for patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer: a single-institution experience
by: Mohamed A. Daoud, et al.
Published: (2016-03-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Monoclonal antibodies at the Oncology Institute of Vojvodina: 5-year expenditure
by: Jelić Marija, et al.
Published: (2012-01-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01)

First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
by: Vogel Arndt, et al.
Published: (2018-05-01)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
by: Tetsuji Terazawa, et al.
Published: (2019-06-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
by: Buchler T, et al.
Published: (2018-12-01)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
by: Tang XM, et al.
Published: (2017-12-01)

The effect of chemotherapy and cetuximab on the number and size of liver metastases in breast cancer
by: Baltić Vladimir
Published: (2005-01-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
by: Jiang W, et al.
Published: (2018-07-01)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
by: Kimberly A. Lowe, et al.
Published: (2019-05-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
by: Maria Debora De Pasquale, et al.
Published: (2020-02-01)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
by: Ankur Bahl, et al.
Published: (2020-06-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Chemotherapy options for metastatic colorectal carcinoma: First, second, third line...
by: Tomašević Zorica I., et al.
Published: (2003-01-01)

Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
by: Satoshi Dote, et al.
Published: (2018-10-01)